Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...

Neurocrine Biosciences shares new data supporting Ingrezza's effectiveness in older adults with tardive dyskinesia. Read more ...

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story ...

Fintel reports that on April 15, 2025, Needham upgraded their outlook for Neurocrine Biosciences (NasdaqGS:NBIX) from Hold to ...

Fintel reports that on April 14, 2025, RBC Capital upgraded their outlook for Neurocrine Biosciences (NasdaqGS:NBIX) from ...

Biosciences announced publication of a post-hoc analysis from two 48-week studies, the KINECT 3 extension and KINECT 4, ...

A physician survey for Neurocrine Biosciences Inc's NBIX +1.72% Get Free Report Crenessity suggests "strong uptake across all patient segments," according to Needham. The Neurocrine Biosciences ...

During the last three months, 16 analysts shared their evaluations of Neurocrine Biosciences NBIX +1.72% Get Free Report , revealing diverse outlooks from bullish to bearish. The following table ...

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $185.00.

Learn more about whether Neurocrine Biosciences, Inc. or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Neurocrine Biosciences announced that its Board of Directors has authorized a stock buyback program on Friday, February 21st that authorizes the company to buyback $500.00 million in shares.